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Abstract 
 
Background: The overuse and misuse of antibiotics decreases their effectiveness and results in 
increasing bacterial resistance which is considered an international public health crisis. 
Antibiotics are one of the most commonly used groups of medicines in peadiatric patients 
however there are limited data available on the usage of antibiotics in paediatrics globally but 
especially in South Africa. The aim of this study was to conduct a retrospective review of 
antibiotics used in paediatric patients in intensive care. 
 
Method: This study reviewed antibiotic therapy from patient charts in the Intensive Care Unit at 
Charlotte Maxeke Johannesburg Academic hospital. The review was done from 15 January 2016 
to 15 February 2016 and 15 January 2017 to 15 February 2017. 
 
Results: There were 40 files reviewed for 2016 and 55 files for 2017. Most patients (2016: 78% 
and 2017: 60%) were neonates aged between 0 -3 months. There were 15 antibiotics prescribed 
in 2016 and 2017 that differed between the two study periods. The most frequently prescribed 
antibiotics in 2016 were: vancomycin (19%), imipenem (18%), ampicillin (11%) and gentamycin 
(11%). In comparison in 2017, the most frequently prescribed antibiotics were meropenem 
(21.7%) vancomycin (20.8%) and co-amoxiclav (11.7%). In both periods majority of patients 
received two antibiotics as therapy during their ICU stay, 47.5% in 2016 and 40% in 2017. The 
average numbers of days in ICU were 5 days in 2016 and 4 days in 2017. Diagnosis 
classifications were similar between the two study periods. Cultures (blood) were ordered in 73% 
(2016) compared to 75% (2017). C-reactive protein samples were taken from 85% of patients in 
2016 and 82% in 2017. In 2017, there were 46.2% (n=36) of doses with a hang time less than 60 
minutes and 32.5% (n=26) in 2016.  
 
Conclusion: This study showed that most antibiotics were prescribed empirically with imipenem 
and vancomycin the most used combination antibiotic therapy in 2016, meropenem and 
vancomycin in 2017. Majority of patients received two antibiotic therapies during their ICU stay. 
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CRP and cultures (blood) were frequently ordered and hang time mostly documented. 
Prescription of antibiotics was mostly compliant with the unit antibiotic prescription guidelines.  
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Chapter 1 
 
INTRODUCTION 
1.1 Introduction  
This chapter will provide an overview of the importance of antibiotics, global concerns related to 
overuse and inappropriate use of antibiotics as well as concerns related to antimicrobial 
resistance. It also briefly discusses antibiotic use in paediatric patients, challenges associated 
with antibiotic use in paediatrics, serious adverse events, antimicrobial stewardship programme 
and availability of antibiotics in hospital as well as outlining the aim and objectives of this study. 
1.2 Background 
Antibiotics, discovered in the early 20th century, considerably changed healthcare and improved 
medicine globally. They reduced morbidity and mortality from infectious diseases. Optimal 
utilisation of the existing and recently developed antibiotics is important in ensuring continuous 
benefits and provision of effective care to patients (Barlam et al, 2016). 
Antibiotics are important for the treatment of very sick patients such as those admitted in the 
Intensive Care Units (ICUs), those with weakened immune systems due to transplantation, 
chemotherapy or HIV, and those with bacterial infections. Antibiotics are frequently prescribed 
to critically ill patients worldwide and have significantly improved patient’s management by 
improving clinical outcomes of infections (Paruk et al, 2012 Magsarili et al, 2015). Recent 
evaluation suggests that the discovery and use of antibiotics have brought about an additional 20 
years of life expectancy (Mendelson, 2015).  
1.3 Antibiotic use in Paediatrics 
Antibiotics are lifesaving therapy for children with bacterial infections and are the most 
commonly recommended treatment to children (Rogawaski et al, 2017). Antibiotics are also the 
most frequently prescribed medications in neonatal ICU with nearly 1% of neonates receiving 
antibiotic therapy in developed countries (Tzialla et al, 2015). 
 There are challenges associated with the use of antibiotics within the paediatric population 
(Magsarili et al, 2015). Those challenges include the fact that children have special medical 
needs which include the need for different antibiotic dosing requirements and they may react 
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differently to treatment. Furthermore, there are also difficulties with regards to confirmation of 
diagnosis in infants and children since they frequently present with non-specific signs and 
symptoms. 
There is increasing evidence that improper or excessive usage of antibiotics in neonatal ICU 
leads to serious adverse event (Cantey and Patel, 2014). Those serious adverse outcomes include 
the emergence of multidrug-resistance (MDR) organisms linked to endemic or epidemic 
infections, increased rates of invasive candidiasis, necrotising enterocolitis, late onset sepsis or 
death. Infection with antibiotic resistant organisms is associated with several challenges such as: 
delay in commencing with effective antibiotic therapy, limited alternative treatment options, 
increased morbidity and death rate, lengthen hospital stay and increased costs of hospitalization 
(Ballot et al, 2012). 
Most antibiotics used in infants do not have Food and Drug Administration (FDA) labelling 
resulting in clinicians often prescribing these antibiotics “off-label” to infants without clinical 
trial data to support dose selection. Ampicillin and clindamycin are examples of commonly used 
antibiotics in infants even though the FDA label has no specific dosing for infants and does not 
address dosing in premature infants and infants less than one month old (Pineda and Watt, 2016). 
Few registered medications have dosing indications for children and infants and therefore 
understanding of the usage or drug administration in children and infants becomes important to 
the practice of medicines in peadiatrics (Mabila et al, 2016).  There is also a lack of data on 
antibiotics utilisation in children (Palcevski et al, 2003). In addition, both Shipp et al (2016) and 
Patel and Saiman (2012) pointed out the fact that there are limited guidelines on antibiotic 
stewardship in neonatal ICU. They further suggested that antibiotic stewardship principles can be 
implemented in the neonatal ICU as well. Those principles include correctly selecting patients 
who requires antibiotic treatment, use of locally available epidemiology data to assist with choice 
of empiric therapy, not prescribing antibiotics with overlapping activity, using culture results to 
modify antibiotics dosing, monitoring adverse events and optimising dosage, appropriate 
administration route and treatment duration. Despite positive results associated with antibiotics 
stewardship programmes (ASPs) in adult patients, there is a lack of data related to experiences of 
ASPs in neonatal settings (Tzialla et al, 2015).  
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1.4 Description of antibiotic availability in the hospital 
The hospital in which the study was conducted is a public tertiary hospital. As a public 
institution with limited financial resources, not all antibiotics registered in South Africa are 
available for prescription in the hospital. Prescribers are generally required to adhere to the 
Essential Medicine List (EML, 2014 edition) while prescribing. The process of prescribing 
antibiotics in the unit is illustrated in Figure 1. Antibiotics are prescribed on the ICU chart by the 
attending physician. For those antibiotics that are available in ICU stock, dosing can occur 
immediately. Antibiotics not available from ICU stock are ordered from the pharmacy on a per 
patient basis, accompanied by appropriate documentation. The hospital has a list of specific 
antibiotics, for example colistin, where the prescriber needs permission from a specialist or the 
head of the unit to prescribe the antibiotic, furnished with supporting documentation such as 
culture results. The antibiotics ordered are recorded manually when dispensed by the pharmacy.  
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Figure 1: Ordering process followed for antibiotics  
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There is limited information regarding the usage of antibiotics in paediatric patients, especially in 
South Africa. This study will help fill this gap by documenting the usage of antibiotics in a 
paediatric ICU. 
1.5 Aim and Objectives 
Therefore, the aim of the study was to conduct a retrospective record review of antibiotics 
utilised in paediatric patients in the ICU. To achieve this aim, the following objectives were 
outlined: 
a. To record the antibiotics prescribed in terms of   frequency, dosage and duration. 
b. To categorise the prescribed antibiotic indications in terms of it being prophylactic (P), or 
empiric (E) or definitive (D). 
c. To document if cultures and specific infection markers such as C-reactive protein (CRP) 
were ordered in relation to antibiotic prescribed.  
d. To calculate the hang time of antibiotics prescribed. 
e. To compare the two study periods in 2016 and 2017.  
 
1.6 Conclusion  
This chapter provided a short introduction to the study and described the process in which 
antibiotics are available in the hospital. The chapter concludes with the stating of the problem 
statement and the outlining to the study’s aim and objectives.  
 
The next chapter provides an in-depth review of the literature.     
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Chapter 2 
LITERATURE REVIEW 
2.1 Introduction  
This chapter reviews the literature relating to the emergence of antimicrobial resistance, 
mechanisms of resistance as well global concerns of increasing antimicrobial resistance. It will 
also discuss the importance of global interventional strategies such as antimicrobial stewardship 
programmes to curb the emergence of antimicrobial resistance.  
2.2 Antibiotic Resistance  
Antibiotic use comes with toxicities and adverse events, the most critical being antibiotic 
resistance (Magsarili et al, 2015). As a result of the overuse of antibiotics, there is a need for 
effective control and regulation of antibiotics to avert antibiotic resistance (Chunnilall et al, 
2015).  Processes and procedures should be in place to ensure that antibiotics are properly 
prescribed, dispensed and that an appropriate route of administration is selected.  
There is an existing worldwide apprehension that there is a drive towards the post antibiotic era 
brought about by several years of imprudent antibiotic use which is causing the emergence of 
multi drug resistant bacterial infections (Boyles et al, 2013). 
There is a global worry regarding overuse, misuse and inappropriate use of antibiotics which has 
resulted in an international growth in bacterial resistance to antibiotics. Recently, the worldwide 
surge in bacterial resistance to antibiotics has led to a concerning situation where normal 
infections that were previously easy to treat have become difficult to treat, requiring second line 
or third line antibiotics. Some of the common infections have become incurable (Boyles et al, 
2017). 
 
Resistance to antibiotics is considered to be the greatest current public health threat. It has been 
estimated that if the rate of increase in drug resistance is not slowed, deaths associated with drug 
resistance will increase to 10 million annually globally by 2050 (Goff et al, 2017). There are also 
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cost implications to health care systems related to antibiotics resistance. This is due to the 
excessive cost of second and third line antibiotics and additional hospital stay by patients. 
The mechanisms in which bacteria have become resistant to antibiotics vary and are 
multifaceted. Currently, bacteria have developed resistance to numerous categories of available 
antibiotics. The most frequent form of resistance is the one which is acquired and conveyed 
horizontally through the conjugation of a plasmid. Novel mechanisms of resistance have resulted 
in concurrent development of resistance to various antibiotic classes producing dangerous MDR 
bacteria strains, also known as “superbugs” (Alanis, 2005).  Selective pressure by antimicrobial 
drugs is by far the most central cause for the growth of microbial resistance (Shankar et al, 
2003). 
There is concern related to the increasing spread of colistin resistance. Sprenger and Fukuda 
(2016) indicated that resistance to colistin develops through two mechanisms. The first one is 
triggered by increased colistin usage, resulting in emergence and spreading of colistin-resistant 
mutants normally related to chromosomal mutation. The second one is associated with the 
discovered plasma-mediated polymixin resistance gene, mcr-1, in Escherichia coli isolated from 
animals in Shanghai. 
Bacterial resistance continues to evolve, leading to some pathogens that were considered routine 
to treat becoming resistant to almost all antimicrobial agents There are great concerns related to 
the emergence of vancomycin resistance in Staphylococcus aureus and carbapenems resistance 
in strains of Enterobacter and Klebsiella pneumoniae (Brink, 2005).  
Clinical practice has shown that broad spectrum antibiotics predispose patients for resistant 
bacteria than narrow spectrum antibiotics (Isaacs, 2006). Multi-resistant bacteria are causing 
several challenges in neonatal ICUs.  There are concerns that the use of ampicillin and third 
generation cephalosporin selects for Gram-negative bacilli which increases extended spectrum β-
lactamases (ESBL) production. ESBLs render microorganism resistant to many antibiotics. 
Similarly, carbapenems, such as imipenem and meropenem are used in laboratories to promote 
the production of β-lactamases. Therefore the over usage of imipenem and meropenem could 
8 
 
select β lactamase- producing organisms, as well as microorganisms which are not susceptible to 
imipenem. 
2.3 Antibiotic usage in paediatrics 
It is estimated that at least 40% (3.1 million neonate deaths each year) of under-five deaths 
globally happens in the neonatal phase (Eman et al, 2015). Majority of these deaths, 
approximately 1 million, are related to infectious causes including neonatal sepsis, meningitis 
and pneumonia. 
Infections are common and significant complications in the paediatric population. Most infants 
admitted to ICUs are exposed to antibiotics. There is a lack of infant’s specific dosing regimens 
and as such doses are frequently extrapolated from data in adults or older children. This may 
result in an increased risk of drug adverse events and lack of clinical effectiveness. It is 
important to determine appropriate dosing regimens for this population (Pineda and Watt, 2016). 
Nosocomial infections are one of the most common causes of the increased death rate and 
morbidity in neonatal ICUs (Mohammed and Seifi, 2014). Mohammed and Seifi pointed out that 
nosocomial infections include blood stream infections, pneumonia, urinary tract infections, 
meningitis, secondary skin infections, eye, ear, nose or throat infections. They further noted that 
the contributing microorganisms could be bacterial, viral, or fungal in origin. Furthermore, they 
indicated that microorganisms causing neonatal infections are not the same from country to 
country and they can also differ within different ICUs as well as changing within years in the 
same setting. This variation requires ongoing effective surveillance to evaluate the epidemiology, 
associated risk factors and causative organisms in order to understand the epidemiology of 
nosocomial infection locally. 
 
Strong emphasis should be placed on the importance of optimising the use of the current 
antibiotics in paediatrics (Doofaeff et al, 2016). Antibiotic use can be optimised by making use 
of data from pharmacokinetic studies. There are several challenges associated with conducting 
pharmacokinetic studies in critical ill neonate and paediatric patients. These include the small 
blood volumes in children, limited study consent rates, challenges with the measurement of drug 
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concentration due low drug volume and limited experience in the field of paediatric modelling. 
They concluded that current antibiotic doses for critically ill paediatric patients are frequently 
suboptimal because of poor understanding of different pharmacokinetic properties. 
 There are other challenges associated with prescribing antibiotics to the paediatric populations 
such as lack of suitable formulations or doses, which leads to the need for the preparations of 
extemporaneous formulations and diagnostic uncertainty since infants and children commonly 
present with non-specific symptoms (Magsarili et al, 2015). In addition, they indicated 
challenges with paediatric patients in ensuring optimal dosing in relation to their age, body size 
and disease condition. 
Leroux et al (2015) further pointed out that few antibiotics have validated clinical trials data to 
get a marketing authorization for neonatal prescription and the majority of them are used off-
label. They indicated that there is a shortage of clinical trials data to support and ensure optimal 
dosing recommendations for almost all antibiotics in neonates. They further pointed out that this 
is demonstrated by the two examples of amikacin and metronidazole. They showed that they 
were 19 different neonatal dosing regimens proposed for amikacin in literature. In addition, they 
observed that there were only 2 population pharmacokinetic clinical trials published with few 
number of neonates (n=32) even though the drug has been used for several years as a treatment 
for complicated abdominal infections in neonates. 
Brinkman et al (2015) pointed out that vancomycin, which is one of the most frequently 
prescribed antibiotics in paediatric ICU is associated with adverse effects such as nephrotoxicity 
and ototoxicity at a suboptimal concentration level. They further pointed out that ICU patients 
have a greater possibility for development of nephrotoxicity than non-ICU patients.  
2. 4 Antibiotic Resistance in peadiatrics 
Antibiotics resistance in bacteria is continually evolving and presents an increasing burden in all 
populations, including children. Prolonged duration of antibiotic use in the neonatal population 
promotes many disease stimulating alterations such as changes in the gut microbiota. 
Modifications in the gut flora causes reduced gut microbial variety which is associated with early 
side effects such as necrotizing enterocolitis and possible life-long consequences such as 
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increased possibility for obesity and inflammatory disease conditions. In addition, antibiotic 
therapy in neonatal phase was connected to reduced wealth of protective commensal anaerobic 
bacteria which offer colonization resistance against antibiotics resistant bacteria and potentially 
pathogenic bacteria like Enterobacteriaceae and Clostridium difficile. Over usage of antibiotic 
during neonatal period is generally linked with an added risk of antibiotic resistance 
development, especially ESBL producing Gram-negative bacteria and other multi drug resistance 
(MDR) bacteria (Fjalstad et al, 2017). Medernach and Logan (2017) reported that antibiotic 
resistant infections are growing in children globally as a result of the selective pressure offered 
by the inappropriate usage of broad-spectrum antibiotics. They further indicated that there are 
high cases of adverse events of polymyxins (polymyxin B and colistin) in children such as 
neurotoxicity and nephrotoxicity. 
2.5 Antimicrobial stewardship 
The United Nations and the World Health Organization (WHO) have designated antimicrobial 
resistance as a main health priority. They have developed action plans to reduce antimicrobial 
resistance in all health settings. They advocated for the establishment of institutional APSs as a 
key intervention to reduce antibiotic consumption in hospitals and to address high rates of MDR 
bacteria (da Silver et al, 2017). WHO further emphasized the need for coordinated interventions 
and joint approach. The aim of the approach is to support poor countries in optimizing antibiotic 
usage through learning and stewardship programs. This will require the need for the formulation 
of strategies and road map to combat the increase of antibiotic resistance. The plan centred on 
the need for APS (Goff et al, 2017).  
Lee et al (2016) further pointed out that the primary goal for ASPs is to improve patient 
outcomes as well as reducing the negative after effect of antibiotic use. The secondary goals of 
reducing antibiotic purchasing and healthcare cost related to the antibiotic resistance are the 
expected favourable consequences of appropriate prescribing  
Sameer and Saiman (2012) also mentioned that the main aim of antimicrobial stewardship is to 
optimize clinical outcome while reducing adverse consequence of antimicrobial use, including 
side effects and the emergence of resistance. They further stated that primary focus of ASPs 
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should be a continuous assessment of the need for antibiotics, the proper choice of dose regimen, 
and the selection of appropriate route of administration.  
Goff et al (2017) discussed several core strategies for implementation of ASPs. Those discussed 
strategies included prospective audit and feedback, formulary restriction and preauthorisation. 
Several other supplemental strategies and interventions such as education, guidelines, 
reassessment of the choice/duration, antibiotic order form, dosage optimisation and selection of 
oral route of administration were also highlighted. 
In addition, Spyridis et al (2015) also indicated that important action required to address the 
problem of antimicrobial resistance is to evaluate and modify the way antibiotics are used. They 
also emphasized the fact that antimicrobial stewardship programme (ASPs) intend to promote the 
appropriate use of antibiotics. They further discussed the urgent need for establishment of ASPs 
in paediatric’s departments. They pointed out that one of the most important components of 
ASPs is the development and implementation of evidence-based antibiotic prescribing guidelines 
providing a standard approach to the optimal selection, dosage and duration of antibiotic therapy. 
Few European hospitals participating in their study have comprehensive antibiotic prescribing 
guidelines for common paediatric infections and majority uses a wide mixture of reference 
sources. Guidelines most commonly available were those for upper respiratory tract infections, 
urinary tract infection and normal sepsis. 
 
Ballot et al (2012) added that antibiotic stewardship, including appropriate selection and 
administration of antibiotics, de-escalation of therapy, and a multidisciplinary team approach to 
managing neonatal sepsis, is recommended to limit inappropriate antibiotic use and prevent the 
development of antimicrobial resistant organisms. 
Cantey and Patel (2014) discussed neonatal ICU antibiotics management strategies which are 
necessary to optimize clinical outcomes while minimizing the unintended consequences of 
antibiotic therapy. They pointed out several useful antimicrobial metrics for neonatal ICU 
including: avoiding unnecessary antibiotic use, reducing broad-spectrum antibiotic use and 
avoiding inadequate therapy. They further discussed the following suggested strategies for 
stewardship in neonatal ICU: diagnosis; empiric therapy; dose optimization; prescriber audit and 
feedback and duration of therapy.  
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Ensuring that patients receive antibiotics timeously from recognition of onset of infections is part 
of comprehensive management strategy to ensure timely intervention as part of the antibiotic 
stewardship strategies. Mok K et al (2014) recommended starting of broad-spectrum antibiotics 
within 1 hour of recognition of severe sepsis or septic shock. They pointed out that there was 
increasing evidence supporting that promptly and appropriate antibiotic therapy improves 
morbidity and mortality. This was also supported by Messina et al (2015) study which showed 
that ensuring that patients receive antibiotics timeously is important in the treatment of patients 
with infections.  They indicated that the rate of death of patients increases by 7.6 % for every 
hour of delay in the administration of antibiotics therapy in patients with sepsis. They further 
concluded that due to logistics within hospital, the time passed from prescription to the actual 
administration or “hang time” can frequently be several hours due to possible barriers such as: 
delay of getting prescription order to the pharmacy, delays in transferring medication from the 
pharmacy to the wards or reconstitution of intravenous antibiotics by nursing staff. 
2.6 Antibiotic Stewardship in South Africa  
In South Africa the EML and the standard treatment guidelines (STGs) have been developed to 
guide prescribers in the public sector. The South African Antibiotic Stewardship Programme 
(SAASP) has a guideline which is also aligned to the EML and the STGs. This guideline 
provides an algorithmic approach to prescribing and further information on treatment duration. 
This guideline does not include paediatric treatment standards. The SAASP developed an 
antibiotic prescription chart to be used for infection episodes and antibiotic prescriptions 
(Mendelson, 2015).  
 
An antibiotic prescription chart was designed to focus antibiotic prescribing on distinct infection 
episodes. The chart requires the prescribing doctor to define the following parameters for each 
infection episode; the indication for antibiotic, whether antibiotics were being prescribed on 
prophylactic, empiric or definitive; whether the infection was community or hospital-acquired, 
diagnosis and whether appropriate specimens had been sent for laboratory culture before or after 
antibiotics had started (Boyle’s et. al, 2013).  
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2.7 Conclusion  
This chapter provided an in-depth review of available literature on antibiotic resistance, 
mechanism of resistance, antibiotic use in paediatrics and antibiotic stewardship programme. 
The next chapter will detail the methodology employed in this study. . 
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Chapter 3 
 
METHODOLOGY  
3.1 Introduction  
This chapter discusses the methodology of the study. It provides information related to the 
purpose of the study, study site, ICU empiric antibiotics guidelines, study design, study period, 
data collection methods, statistical analysis and ethical considerations.  
3.2 Purpose of the Study 
The purpose of this study was to conduct a retrospective record review of antibiotics utilized in 
paediatric patients in an ICU at two-time periods. There was however no intervention made 
between these two study months.   
3.3 Study Site 
The study was conducted at Charlotte Maxeke Johannesburg Academic Hospital’s Paediatric 
ICU. The hospital is a public academic hospital located in Parktown, Johannesburg, Gauteng 
Province. This unit has 12 beds which are reserved for any paediatric patient needing this level 
of care.  
It was noted during discussions with the ICU unit that they followed specific admission process 
flow in the ICU (Figure 2). They indicated that once neonates are admitted in ICU and there is a 
suspected nosocomial infection, blood culture and CRP samples are taken, and the neonates are 
immediately started on empiric therapy. 
In consultation with the ICU unit, they indicated that the unit’s antibiotic treatment 
guideline/protocol outlines the following empiric treatment algorithm as outlined in Table 1.  
Regimen A or B is used in neonates depending on the suspected organism. For older children, 
the ampicillin/cefotaxime/ceftriaxone is the preferred antibiotics to be used empirically. These 
regimens provide broad-spectrum coverage. It was also confirmed with the unit that amoxicillin 
was used prophylactically post-operatively. 
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Table 1: Charlotte Maxeke hospital ICU empiric antibiotics treatment guideline 
                      Neonates (Empirically) 
Regimen: A: Gentamycin plus Ampicillin 
                 B: Meropenem plus Vancomycin or 
                      Amikacin plus Tazocin 
                      Paediatric (Empiric) 
                 C: Co-amoxiclav/cefazolin 
                 D:  Ampicillin/cefotaxime/ceftriaxone  
  
 
 
     
  
                                                                              
 
Figure 2: Patients admission process flow 
 
 
 
3.4. Study Design  
This was a retrospective review of patient ICU charts.  
3.5 Study period 
Retrospective chart review was done for the following periods: 15 January 2016 to 15 February 
2016 and 15 January 2017 to 15 February 2017. There was no intervention made between the 
two study periods. This study wanted to document utilization of antibiotics in two consecutive 
years. 
 
Neonate admitted 
in ICU 
Suspected 
Nosocomial 
Infection 
Cultures and 
CRP Samples 
taken 
 Start Empiric 
Therapy 
16 
 
3.6 Study Population and Sample Selection 
Paediatric patients admitted to paediatric ICU who were prescribed and administered antibiotic 
during the study dates were included in the study. Patients who were not prescribed antibiotics as 
well as those whose records were not available were excluded from the study.  The sample 
consisted of 40 patients in 2016 and 55 patients in 2017. 
3.7 Data collection 
Data was transcribed from the ICU chart onto the data collection tool (Appendix 1). The ICU 
charts document all the medication prescribed, the amount the patients received and the time the 
dose was administered. The infection markers and laboratory tests are ordered are recorded on 
these charts as well. These charts are kept in the ICU until the patient leaves this unit. After 
which the charts are sent to the record room where they are scanned and stored electronically.   
The data collection tool was a modified version of the South African Antibiotic Prescription 
Chart (Appendix 1).  An antibiotic prescription chart focuses the antibiotic prescription on 
distinct infection episode (Boyles et al, 2013). Permission to use this chart was granted by Prof. 
Mendelson, one of the physicians who designed the chart.  
The antibiotic prescription chart captures the antibiotic prescribed; dose, duration, stated 
indication, microbiology results and the time antibiotics were prescribed and administered for 
each patient. Laboratory results that were not found on the chart were confirmed using the 
National Health Laboratory electronic system (LABTRAK). 
Records were categorized according to the following age groups; 0-3 months, >3 months – 1 
year, >1 – 5 years and older than 5 years. These categories were defined in consultation with the 
head of the unit as they would best describe the patients within their unit.  
Hang time was measured as the time from when the antibiotic was ordered until the dose was 
administered. This was calculated for each dose where the time of prescribing was indicted on 
the ICU chart.  
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3.8 Statistical Analysis 
Data was captured on Microsoft Excel (2010) and statistical analyses were performed on SAS 
(SAS Institute, Carey, NC, USA), Release 9.4.  Quantitative data was analyzed using descriptive 
statistics such as percentages for categorical data and means and standard deviations for 
numerical data.  
3.9 Reliability and Validity of Data 
3.9.1 Reliability  
The data collection tool for this study, the modified version of the South African Antibiotic 
Prescription Chart, was used successfully as the data collection tool for the larger study. 
3.9.2 Validity  
To ensure validity of the study results the researcher collected all the study results for both time 
periods.     
3. 10 Ethical considerations 
This was a sub-study of “Situational Analysis of Antibiotic Stewardship in Gauteng Public 
Hospital” (M141141 – Appendix 5). Hospital approval to conduct this study was obtained 
(Appendix 7). Permission to conduct this sub-study was received from the Human Research 
Ethics Committee of the University of Witwatersrand (M1703110- Appendix 6). Management of 
patient records was as follows:  
• Each patient was assigned a study number. 
• List of patients and assigned numbers were kept in a locked cupboard which was only 
accessible to researcher and supervisor.  
• No patient was identifiable from the data collection tool (patient’s names, hospital 
numbers and date of birth were not collected). 
• Prescribers’ details were not recorded.  
• No files were copied or removed. 
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3.11 Conclusion  
This chapter described the study methodology including the study design, data collection 
methods, data analysis and ethical considerations. It also explained the study setting and the 
guidelines for prescribing antibiotics for empiric and prophylactic use in the ICU.    
The next chapter presents the findings of this study.  
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Chapter 4 
 
RESULTS 
4.1 Introduction  
This chapter discusses the results of the study and provides data to support  the objectives of the 
study. It documents the antibiotics prescibed, their dosage and frequency, diagnosed conditions 
and duration of treatment. Also included  is culture specimens and CRPs ordered as well as 
calculating the  hang time. 
 
4.2 Demographics data comparison  
This study reviewed the usage of antibiotics in 40 patients admitted from 15 January 2016 to 15 
February 2016 and 55 patients admitted from 15 January 2017 to 15 February 2017 in the 
pediatric ICU. There was no significant difference between male and female patients between the 
two periods (Fisher’s exact: p=0.2982). There were 63.6% male patients admitted in 2017 and 
47.5% in 2016.  There was also no significant difference between median weights of patients for 
the two periods under review (Fisher’s exact; p=0.4813). The average numbers of days in ICU 
were 5 days in 2016 and 4 days in 2017 (Table 2).  
Table 2: Demographic data comparison 
  2016 (n=40) 2017 (n=55) P-value 
Age (months), median (IQR) 0.804 (0.144 - 2.856) 2.004 (0.228 – 11.004)    0.3009* 
Weight (grams), median (IQR) 3230 (1465-4555) 3300 (1580-9000)         0.4813* 
Number of Days in ICU, mean 
(Min-Max) 5 (1-16) 4 (1-13) 
 
Gender: Male n (%) 19 (47.5) 35 (63.6) 0.2982* 
Gender: Female n (%) 21 (52.5) 20 (36.4) 
*Fisher’s Exact Test 
 
 
 
20 
 
In both study periods majority of the patients were between 0-3 months (2016: 77.5%, 2017: 
60%). There was no significant difference between the ages of the children between the two 
years (Chi 2 5.193; p=0.1582) 
Table 3: Age sub categorisation 
Age categories 2016 
(n=40) 
2017 
(n=55) 
0- 3months 31 (77.5%) 33(60%) 
>3- 12 months 3 (7.5%) 10 (18.2%) 
>1- 5 years 2 (5%) 8 (14.6) 
>5 years 4 (10%) 4 (7.3%) 
 
 
4.3 Antibiotics Prescribed and frequency 
There were 15 antibiotics prescribed in 2016 and 2017, however these antibiotics differed. The 
most frequently prescribed antibiotics in 2016 were vancomycin (19%), imipenem (18%), 
ampicillin (11%), gentamycin (11%), amikacin (8%), co-amoxiclav (6%) and 
piperacillin/tazobactam (6%). In 2017, the most frequently prescribed antibiotics were 
meropenem (21.7%) vancomycin (20.8%), co-amoxiclav (11.7%), ampicillin (10%), gentamycin 
(9.2%), cefotaxime (5.8%), and piperacillin/tazobactam (5.0%). There were differences between 
the types of antibiotics prescribed during the two review periods. Imipenem (18%), co-
trimoxazole (3%), erythromycin (4%) and ertapenem (1%) were only prescribed in 2016. In 
comparison colistin (2.5%), chloramphenicol (0.8%), and rifampicin (0.8%) were only 
prescribed in 2017. Three carbapenems (imipenem 18%, meropenem 2% and ertapenem 1%) 
were prescribed in 2016, however, in 2017 only meropenem (21.7%) was prescribed. The 
frequency at which vancomycin and gentamycin was similar both in both time periods (Table 4).   
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Table 4: Antibiotics prescribed and frequency 
 
2016 2017 
Antibiotic Prescribed 
(n=15) Frequency 
Antibiotic Prescribed 
(n=15) Frequency 
Amikacin 8 Amikacin 5 
Ampicillin 11 Ampicillin 12 
Cefazolin 3 Cefazolin 4 
Cefotaxime 4 Cefotaxime 7 
Ceftriaxone 2 Ceftriaxone 3 
Co-amoxiclav 6 Chloramphenicol 1 
Co-trimoxazole 3 Cloxicillin 1 
Cloxicillin 2 Co-amoxiclav 14 
Ertapenem 1 Colistin 4 
Erythromycin 4 Doxycycline 1 
Gentamicin 11 Gentamicin 11 
Imipenem/cilastin 18 Meropenem 26 
Meropenem 2 Piperacillin/tazobactam 6 
Piperacillin/tazobactam 6 Rifampicin 1 
Vancomycin 19 Vancomycin 25 
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4.4 Number of antibiotics prescribed per patient 
 There was an observed difference between the percentage of patients that received one antibiotic 
in 2016 (12.5%) versus 2017 (25.45%). The difference was however not statistically significant 
(Fisher Exact, p=0.1931). In both periods the majority of patients received two antibiotics as 
therapy during their ICU stay, 47.5% in 2016 and 40.0% in 2017. Instances when a patient was 
prescribed three and four antibiotics during ICU stay were similar in both the 2016 and 2017 
review period. The highest number of antibiotics prescribed in both time periods was five (2016: 
n=2) (Figure 3).  
 
  
Figure 3: Number of antibiotics patients received during admission to the ICU 
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 4.5 Concurrent use of antibiotics 
In 2016, imipenem and vancomycin were concurrently used 12 times, ampicillin and 
gentamycin concurrently used 9 times and piperacillin/tazobactam and amikacin were 
concurrently used three times. In 2017, meropenem and vancomycin were concurrently used 
19 times, ampicillin and gentamycin concurrently used 11 and piperacillin/tazobactam and 
amikacin were concurrently used on two occasions. Three antibiotics were concurrently used 
eight times in 2016, with ampicillin, gentamycin and trimethoprim/sulfamethoxazole 
concurrent therapy used twice. However, in 2017 three antibiotics were concurrently used six 
times with meropenem, vancomycin and colistin being used concurrently twice (Table 5 and 
6). 
Table 5: Antibiotics administered concurrently in 2016 
    
Antibiotic 1 Antibiotic 2 Antibiotic 3 Times 
used 
Ampicillin Gentamycin  9 
Ampicillin Erythromycin  1 
Ampicillin Gentamycin Erythromycin 1 
Ampicillin Gentamycin Trimethoprim/Sulfamethoxazole 2 
Cefotaxime Imipenem Vancomycin 1 
Cefotaxime Trimethoprim/Sulfamethoxazole  1 
Ceftriaxone Erythromycin  1 
Cloxicillin Cefotaxime  1 
Co-amoxiclav Cefotaxime  1 
Ertapenem Vancomycin Amikacin 1 
Gentamycin Imipenem Vancomycin 1 
Imipenem Vancomycin  12 
Piperacillin/Tazobactam Amikacin Cloxicillin 1 
Piperacillin/Tazobactam Amikacin Erythromycin 1 
Tazocin Amikacin  3 
Vancomycin Imipenem Amikacin 1 
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Table 6: Antibiotics administered concurrently in 2017 
Antibiotic 1 Antibiotic 2 Antibiotic 3 Times 
used 
Ampicillin Gentamycin  11 
Ampicillin Piperacillin/Tazobactam  1 
Cefotaxime Chloramphenicol  1 
Cefotaxime Cloxicillin  1 
Cefotaxime Colistin  1 
Cefotaxime Vancomycin  1 
Ceftriaxone Doxycycline  1 
Meropenem  Amikacin  1 
Meropenem  Vancomycin  19 
Meropenem Vancomycin Cefotaxime 1 
Meropenem Vancomycin Colistin 2 
Piperacillin/Tazobactam Amikacin  1 
Piperacillin/tazobactam  Vancomycin  1 
Vancomycin Amikacin Piperacillin/tazobactam 1 
 
4.6 Indications of Prescribed antibiotics in terms of it being either prophylactic (P), empiric (E) or 
definitive (D) 
It was not indicated in records reviewed whether the prescribed antibiotic was for prophylactic, empirical 
or definitive purposes. The researcher assigned this classification retrospectively according to the 
information provided by the unit. However, it could not be confirmed with the prescriber.  Most of the 
doses given in both study periods were classified as presumed empiric.  There were two presumed 
definitive doses in each study period. Five doses in 2016 were presumed empiric initially which changed 
to definitive after reviewing the culture results. Treatment policy/guideline for the unit is that in general 
antibiotics are used empirically until sepsis is ruled out. CRP results and culture results are used to direct 
further treatment action, for example, stopping antibiotics in case of low CRP and negative culture results 
and changing therapy based on sensitivity pattern. 
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4.7 Calculation of dosages 
Doses of antibiotics given to children in ICU are calculated according to weight. In 2016, there were a 
total of 94 doses of antibiotics given to children compared to 123 doses in 2017 (Appendix 8 and 9). 
Doses were recalculated based on dosage guidelines on South African Medicines Formulary (SAMF, 
2016) and recorded weight of children. When calculating the doses, it was seldom found that the value 
calculated was identical to the prescribed dose. Doses where the variation was greater than or equal to 
10% are reported in Tables 7 to 10.   
The calculated doses showed that 22% (n=21) of doses given in 2016 were lower than calculated doses 
(Table 7) as compared to 15% (n=19) in 2017 (Table 9) (p=0.2186 Fishers Exact). There was no 
significant difference between the two periods. There were 3% (n=3) of doses given that were higher than 
the calculated doses in 2016 (Table 8) as compared to 7% (n=9) doses in 2017 (Table 10)  
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Table 7: Doses lower that calculated SAMF doses in 2016 
Antibiotic Dose prescribed 
(mg/kg/dose) 
SAMF(2016) calculated 
dose 
(mg/kg/dose) 
Ampicillin 200 235 
Co-amoxiclav 250 380 
Co-amoxiclav 100 170 
Co-amoxiclav 300 500 
Co-amoxiclav 100 170 
Co-amoxiclav 60 110 
Co-amoxiclav 360 600 
Amikacin 280 342 
Cefazolin 120 184 
Cefazolin 700 1250 
Cefazolin 100 120 
Vancomycin 30 42 
Vancomycin 200 285 
Vancomycin 34 51 
Vancomycin 22 33 
Piperacillin/tazobactam 250 340 
Piperacillin/tazobactam 1 2.5 
Piperacillin/tazobactam 400 440 
Gentamycin 20 38 
Imipenem 44 55 
Imipenem 75 92 
 
 
 
 
 
 
 
27 
 
Table 8: Doses higher than SAMF calculated Doses in 2016 
 
Antibiotic Dose prescribed 
(mg/kg/dose) 
SAMF(2016) calculated dose 
(mg/kg/dose) 
Cefotaxime 270 200 
Cefotaxime 250 215 
Meropenem 60 46 
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Table 9: Doses lower than calculated SAMF doses in 2017 
Antibiotic Dose prescribed 
(mg/kg/dose) 
SAMF(2016) calculated dose 
(mg/kg/dose) 
Amikacin 20 43 
Co-amoxiclav 120 132 
Co-amoxiclav 360 580 
Co-amoxiclav 250 450 
Co-amoxiclav 145 240 
Co-amoxiclav 120 185 
Co-amoxiclav 180 280 
Co-amoxiclav 65 110 
Co-amoxiclav 325 650 
Co-amoxiclav 180 305 
Co-amoxiclav 225 450 
Co-amoxiclav 120 225 
Co-amoxiclav 150 295 
Co-amoxiclav 325 595 
Cefotaxime 400 595 
Cefazolin 400 600 
Meropenem 80 104 
Piperacillin/tazobactam  550 740 
Vancomycin 28 44 
 
 
 
 
 
 
 
 
29 
 
Table 10: Doses higher than calculated SAMF Doses in 2017 
Antibiotic Dose prescribed 
mg/kg/dose 
SAMF(2016) calculated dose 
mg/kg/dose 
Cefotaxime 140 105 
Cefotaxime 275 205 
Cefotaxime 120 89 
Cefotaxime 190 143 
Ceftriaxone 1800 1380 
Vancomycin 186 80 
Vancomycin 115 84 
Vancomycin 28 44 
Meropenem 205 192 
 
4.8 Duration of antibiotics 
The longest antibiotic duration in 2016 was erythromycin (12.5 days) and cefotaxime (8.33 days) 
in 2017. Vancomycin had the shortest duration (0.25 days) in 2016 whereas in 2017 there were 
four antibiotics with shortest duration (ampicillin, cefotaxime, co-amoxiclav, meropenem and 
vancomycin), all with 0.33 days duration (Table 11). Medical records of patients did not have 
information on why certain antibiotics have one day or less than one day duration. Rationale for 
1 day duration could not be retrospectively determined. 
 
In both periods, most antibiotics duration was five days or less. Four antibiotics had a duration of 
between 5 days and 10 days in 2016 and in 2017 there were 5 antibiotics with the same duration. 
There was only one antibiotic in 2016 with a duration of more than 10 days and none in 2017 
(Figure 4) 
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Table 11: Average duration of prescribed antibiotic in 2016 and 2017 
Prescribed Antibiotic 
2016 2017 
Average days on antibiotics 
(min-max) 
Average days on 
 antibiotics 
(min-max) 
Ampicillin 1.60 (0.333-3.500) n= 16 2.25(0.333-4.5) n= 17 
Amikacin 2.63 (1.000-5.000) n= 8 2.00(1.000-4.000) n= 4 
Cefotaxime 3.75 (1.000-10.333) n= 4 2.14(0.333-8.333) n= 7 
Ceftriaxone 2.83 (0.667-5.000) n= 2 2.50(2.000-3.000) n= 3 
Cefazolin 1.33 (1.000-2.000) n= 3 1.25(1.000-1.333) n= 4 
Co-amoxiclav 2.00 (1.000-4.000) n= 6 2.80(0.333-7.330) n= 13 
Co-trimoxazole 5.56 (3.000-7.000) n= 3 - 
Colistin -- 3.78(1.000-5.333) n= 3 
Cloxicillin 1.25 (0.500-2.000) n= 2 1.00(1.000-1.000) n= 1 
Chloramphenicol - - 
Doxycycline - 3.00(3.000-3.000) n= 1 
Ertapenem 2.50 (2.500-2.500) n= 1 - 
Erythromycin 4.19 (0.500-12.500) - 
Gentamicin 2.20 (1.000-4.000) n=10 2.73(1.000-5.000) n= 11 
Imipenem/cilastin 3.69 (0.333-9.000) n= 18 - 
Meropenem 4.67 (2.000-7.333) n= 2 3.41(0.333-8.667) n= 25 
Piperacillin/tazobactam 2.33 (0.667-4.000) n= 6 2.40(1.000-4.000) n= 5 
Rifampicin - 8.00(8.000-8.000) n= 1 
Vancomycin 3.26 (0.250-10.000) n= 19 2.06(0.333-4.667) n= 23 
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Figure 4: Duration of antibiotics prescribed (days) 
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4.9 Missed doses 
There were the same number of missed doses in 2016 (n=10) compared to 2017 (n=10). It is not 
possible to confirm retrospectively if these doses were given but not recorded, whether additional 
instructions were given to nurses to delay the dose or if the antibiotic was out of stock. 
 
Table 12: Average number of doses missed 
  
Antibiotic 
2016 2017 
Average number of doses 
missed 
Average number doses 
missed 
Ampicillin 0.82 0.58 
Cefotaxime 1.00 0.14 
Ceftriaxone - 0.67 
Cefazolin - 0.75 
Co-amoxiclav 1.12 0.36 
Co-trimoxazole 0.67 - 
Colistin - 1.00 
Doxycycline - 0.00 
Erythromycin 1.50 - 
Gentamicin 0.10 0.09 
Imipenem/cilastin 0.89 - 
Meropenem 1.00 1.08 
Piperacillin/tazobactam 0.33 0.78 
Vancomycin 0.90 1.25 
 
4.10 Hang time 
Time that the dose was prescribed and administered was documented in 80 doses during 2016 
and 78 doses during 2017 from which hang time was calculated. Doses where prescriptions were 
written after antibiotics were administered and those where prescriptions were written but 
antibiotics were given the following day were excluded from these calculations. The exclusion of 
doses that were given the following day was to eliminate instance were verbal order was given to 
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the nurses to delay initiating therapy until the following day in cases where patients were 
transferred to ICU from the general ward already on antibiotics. In 2017, there were 46.2% 
(n=36) doses with hang time less than 60 minutes and 32.5% (n=26) in 2016 study. A similar 
pattern was observed for doses with hang times greater than 180 minutes, which occurred in only 
17.9 % of doses in the 2017 study period compared to 32.5% in the 2016 study period. Hang 
times between 61-180 min show a similar pattern between the two study periods (Table 13). 
There was no significant difference between the hang times for 2016 compared to 2017 (Chi2 
5.186. p=0.0747). 
 
Table 13:  Doses hang time  
Hang time  
2016 
(n=80) 
2017 
(n=78) 
 ≤60 Min 26 (32.5%) 36 (46.2%) 
61-180 Min 28 (35%) 28 (35.9%) 
≥180 min 26 (32.5%) 14 (17.9%) 
 
4.11 Blood cultures ordered 
Blood cultures (blood) were ordered in 73% (n=29) of patients in 2016 and 75% (n=41) in 2017  
Total number of cultures taken in 2016 was 53 as compared to 62 cultures in 2017. There were 
19% (n=10) positive cultures in 2016 as compared to 5% (n=3) in 2017 (Table 13). There was no 
significant difference in the blood culture profile between 2016 and 2017 (Chi25.469, p=0.0649). 
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Table 14: Culture specimen results 
  
2016 
  
2017 
  
Prescribed Antibiotic 
Growth 
status Sensitivity 
Growth 
status Sensitivity 
Ampicillin  No growth  N/A  No growth  N/A 
Amikacin Positive Cloxicillin  No growth  N/A 
Cefotaxime  No growth  N/A  No growth  N/A 
Ceftriaxone  No growth  N/A  No growth  N/A 
Cefazolin  Positive 
 Meropenem 
  Positive 
 Penicillin/Ampicillin 
 Cloxicillin 
Co-amoxiclav  Positive  Vancomycin  No growth  N/A 
Co-trimoxazole  Not done  N/A  N/A  N/A 
Colistin  N/A  N/A  No growth  N/A 
Cloxicillin  Positive  Cloxicillin  Not done  N/A 
Chloramphenicol  N/A  N/A  N/A  N/A 
Doxycycline  N/A  N/A  Not done  N/A 
Ertapenem  No growth  N/A  N/A  N/A 
Erythromycin  No growth  N/A  N/A  N/A 
Gentamicin  No growth  N/A  Positive  Colistin 
Imipenem/cilastin  Positive  Imipenem  N/A  N/A 
Meropenem  No growth  N/A  Positive  Fluconazole 
Piperacillin/tazobactam  Positive  Cloxicillin  No growth  N/A 
Rifampicin  N/A  N/A  Not done  N/A 
Vancomycin  Positive  Ceftazidime  No growth  N/A 
 
 
 
 
4.12 Infection markers (CRP) 
It was observed that CRP was routinely used in this unit. CRP samples were taken from 85% 
(n=34) of patients in 2016 and 82% (n=45) of patients in 2017. 
  
4.13 Summary of diagnosis 
Diagnosis classifications were similar between the two study periods (Appendix 4). This is 
consistent with the number and class of antibiotics used during the two study periods. In both 
study periods, the highest number of diagnosis classifications related to surgical procedures, 
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followed by medical and lastly with infections being the least classified diagnosis (Table 14). 
The diagnosis recorded was that which appeared on the ICU chart. This normally reflected the 
initial diagnosis when the patient was admitted into the hospital or ICU. It may not correlate with 
the reason for antibiotics been prescribed. There was no significant difference in the diagnosis 
profile between the two years (Chi2 0.1416, p=0.9317). 
 
Table 15: Summary of diagnosis 
Diagnosis 2016 2017 
Infections 8 8 
Medical 14 11 
Surgery 21 18 
 
4.14 Conclusion  
This chapter provided the results of the study. Similar antibiotics were used in the two time 
periods. Duration of use of antibiotics was short, and the majority of doses were comparable to 
calculated values. Blood cultures and CRPs were ordered routinely. Hang times seemed to 
improve from 2016 to 2017 with more patients receiving their antibiotics within an hour after 
prescription.   
The next chapter discusses the results and relates the study findings to available literature.  
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Chapter 5 
 
DISCUSSION  
5.1 Introduction  
This chapter discusses results of the study and focuses on antibiotics prescribed including dosing 
and duration, hang time measurements as well as, culture specimen and CRPs.  
 
5.2 Antibiotics prescribed 
Antibiotics are frequently prescribed in paediatric ICUs. There are limited studies which have 
reviewed and documented antibiotic utilization in paediatric ICU at public hospitals in South 
Africa. 
This study was a retrospective review of 40 patient files in 2016 and 55 patients in 2017. 
Majority of the patients in both years were neonates.  
The most frequently prescribed antibiotics were vancomycin, imipenem, ampicillin, gentamycin 
amikacin and co-amoxiclav in 2016 whereas in 2017, the most prescribed antibiotics were 
meropenem, vancomycin, co-amoxiclav, ampicillin, gentamycin and cefotaxime. In addition, this 
study showed that colistin, was only used twice during the study period. 
Frequently patients were prescribed two concurrent antibiotics, 47.5% in 2016 and 40% in 2017. 
The most frequently used antibiotics in concurrent therapies were imipenem and vancomycin; 
ampicillin and gentamycin as well as meropenem and vancomycin. 
Imipenem was the most frequently used carbapenem in 2016, with meropenem used less 
frequently, however in 2017, only meropenem was used. Hornik et al (2013) observed small but 
statistically significance difference in the proportion of infants diagnosed with seizure when 
treated with meropenem (5.4%) and 7.6% when treated with imipenem. This provides a possible 
reason for the use of meropenem rather than imipenem. Other reasons could be that selected 
antibiotics are not available on tender and possible stock shortages.  
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Mabila et al (2016) showed that ampicillin, gentamycin, co-amoxiclav, amoxicillin and co- 
trimoxazole were commonly prescribed antibiotics even though their study was based in a 
general ward in South Africa in a public hospital. 
Their study also showed that the use of colistin was very limited, which is consistent with our 
study. This observation is not surprising due to significant side effects concerns with colistin 
(Halaby et al, 2013) and the emergence of colistin-resistant strains among the Gram- negative 
bacteria (Mammina et al, 2012). Furthermore, Brink (2016) also discussed concerns related to 
the use of colistin as results of the latest discovery of two plasmid-mediated genes, (mcr-1 and 
mcr-2) which give resistance to colistin. 
The study results support the ICU algorithm as shown in Figure 3. In both the study periods, the 
highest percentage of prescriptions were in instances where a patient was prescribed two 
antibiotics during their ICU stay, 47.7% (n=19) in 2016 and 40.0% (n=22) in 2017. 
There is also an agreement between this study results and the unit’s antibiotic treatment 
guidelines in terms of concurrent use of antibiotics.  From our study, it was noted that in 2016, 
imipenem and vancomycin were concurrently used 11 times and ampicillin and gentamycin were 
concurrently used nine times. In 2017, meropenem and vancomycin were concurrently used 19 
times and ampicillin and gentamycin were concurrently used 11 times. The selected concurrent 
antibiotic therapy covered both the Gram-positive and Gram-negative organisms.  However, it 
was also noted that it was difficult to assess the appropriateness of concurrent use of antibiotics 
retrospectively as consultation with the prescribing doctor could have explained any differences. 
The unit’s decision for the choice of empiric therapy was based on the surveillance of 
antimicrobial sensitivity patterns in culture isolates done at the unit.  A retrospective review of all 
bacterial isolates in blood cultures obtained for a period of a year observed that Coagulase-
negative staphylococci (CoNS) was the most common isolate overall (19.1%), followed by 
Klebsiella pneumoniae extended spectrum beta-lactamase (12.1%) and Acinetobacter baumanii 
(10.9%). They also noted that Gram-positive infections predominated in early onset sepsis (EOS) 
with Streptococcus agalactiae being the most common isolate. Both Gram-positive and Gram-
negative infections were noted as being prevalent in late onset sepsis (LOS), with CoNS the most 
frequent isolate (Ballot et al, 2012). 
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They confirmed that the above bacteria profile identified during their study informed the current 
empiric treatment guideline for the unit. Based on the bacteria profile, penicillin/ampicillin plus 
an aminoglycoside (gentamycin/amikacin) were confirmed as suitable empiric antibiotic therapy 
for EOS. The selected combination of antibiotic therapy widens the antimicrobial cover and 
provides double coverage. They indicated that vancomycin would provide cover for CoNS 
whereas in critically ill neonates, meropenem plus either gentamycin or ciprofloxacin would be 
the therapy of choice. Alternatively, they indicated that the combination of ceftazidime and 
amikacin would provide cover for the majority of the Enterobacteriaceae and non-fermenters.  
The results from the neonatal unit  study done by Ballot et al (2012) are supported by many 
studies done in neonatal units (Tzialla et al, 2015); Sivanandan et al, 2011). It was emphasized 
that an empiric antimicrobial treatment for LOS should generally cover both Gram-positive and 
Gram- negative microorganisms. They suggested a combination of ampicillin and 
aminoglycosides (gentamycin) or ampicillin and cefotaxime for LOS. In addition, Cantey et al 
(2016) also observed in their study that ampicillin and gentamycin were used for empirical 
therapy for EOS sepsis whereas for LOS, gentamycin and oxacillin were used.  
The results in Chapter 4 must be taken in the context of the high percentage of neonates in the 
ICU. Neonates are immune compromised individuals who are prone to infection (Ballot et al, 
2012). They further indicated that sepsis is a common infection in neonates and that neonatal 
sepsis has a high morbidity and mortality and is not easy to diagnose on presentation. Clinical 
diagnosis on presentation is complex as there are nonspecific signs and symptoms which require 
the start of empirical antibiotic therapy until suspected sepsis is ruled out (Eman et al, 2015).  
Sepsis is a big cause of morbidity and mortality among neonates, with 8.5% incidence of sepsis 
and 20.8% mortality due to sepsis (Motara et al, 2005). In their study EOS was an unusual 
isolate and LOS was more common with CoNS the most common microorganism in LOS. The 
epidemiology of neonatal sepsis and the antibiotic resistance patterns from their study were used 
as a guideline for the management of neonatal sepsis at Charlotte Maxeke Johannesburg 
Academic Hospital. EOS was predominately caused by Gram-negative organisms and therefore 
the recommended empiric therapy choice for EOS was aminoglycosides (gentamicin) plus 
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penicillin (ampicillin). Regarding LOS, the recommended empiric antibiotic therapy was 
vancomycin and carbapenems.  
 The majority (> 95%) of microorganisms causing EOS were susceptible to the two most 
commonly used antibiotic therapies (penicillin and gentamycin or amoxicillin and cefotaxime).It 
was further noted that CoNS constituted 54% of LOS cases. Furthermore, most of LOS isolates 
were susceptible to the two most frequently used empiric antibiotic combinations such as 
flucloxacillin and gentamycin or amoxicillin and cefotaxime as supported by Russell et al 
(2010).  
  
5.3 Duration of antibiotics 
This study showed that in both periods, the duration of most antibiotics was five days or less. 
There were only two antibiotics in 2016 with duration of more than 10 days and none in 2017. 
The longest antibiotic duration in 2016 was erythromycin (12.5 days) and cefotaxime (8.33 days) 
in 2017. 
 
Shorter durations of antibiotic therapy were also observed in Fisher et al, (2009). Their study, 
evaluating antibiotics prescribing practices for pediatric patients (ages 0-13 years) admitted to 
referral hospital in Botswana looked at total duration of antibiotic use. Their study found out that 
15 of 31 patients with lower respiratory tract infection had median duration of antibiotic use of 
9.5 days (IQR=5-10 days) with 60% of these patients having a duration of greater than 7 days. 
They also found out that for most patients with suspected bacterial pneumonia, the duration of 
antibiotic use was longer than the WHO recommendation; however the median total duration of 
9.5 days was less than the often recommended 10 day course in developed countries. Their 
results illustrated that the overuse of antibiotics was not a result of incorrect initiation of 
antibiotic but the failure to stop antibiotic use once there was no longer a concern for infections. 
They further discussed concerns related to the ultimate duration of prescribed antibiotic, firstly 
the fact that the duration of antibiotic use for those with and without an infectious diagnosis was 
similar and secondly that the likelihood that some of the infectious diagnosis were viral in 
etiology, making prolonged courses of antibiotic therapy unnecessary.   
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Sivanandan et al (2011) indicated that there is limited number of well-designed clinical studies 
assessing the suitable duration of empiric antibiotic treatment in negative blood culture sepsis. 
They further pointed out that there is a variation between centers related to the suitable duration 
of empiric antibiotic for suspected EOS in the case of negative blood cultures. The advantages of 
optimal duration of empiric antimicrobial therapy which includes decreasing the emergence of 
antimicrobial resistance, prevention of undesirable alterations in the gastrointestinal flora and 
minimization of avoidable expenses for infants were pointed out in this study. In their 
conclusion, they indicated that the standard practice duration of empiric treatment in neonate 
should be 48-72 hours pending cultures for suspect sepsis and 10-14 days for blood culture 
positive sepsis without meningitis.  
 
5.4 Antibiotics dosing 
Results from this study showed that majority of antibiotics doses given were in compliant with 
doses specified in South Africa Medicines Formulary (SAMF) paediatric dosage guidelines 
(Appendices 8 - 9). Only the doses where a 10% variation in dose was calculated were reported 
as either below or above SAMF recommended doses. There is a paucity of data which confirms 
the acceptable variation. However, the calculated doses did not take into account the severity of 
the infections. The guidelines used in the unit are based on gestational age and birth weight.  
Usage of antibiotics in critically ill neonates and pediatric patients is not well understood, with 
evidence suggesting that current dosing is frequently inadequate (Dorofaeff et al, 2016). A 
European-wide point prevalence study involving 89 neonatal ICUs from 21 countries found that 
75% of vancomycin doses were below the recommended dosage. Furthermore, recommended 
neonates and pediatric antibiotic dosing regimens are often extrapolated from healthy adult data 
using basic empiric scaling factors such as body weight or body surface area. In their conclusion, 
they stated that infections in critical ill neonate and pediatric patients is a challenging health 
issue and current antibiotic regimens for critically ill neonates and pediatrics are suboptimal due 
to poor understanding of altered pharmacokinetic properties (Dorofaeff et al, 2016). 
 
Similarly, despite the widespread use of antibiotics in premature (˂ 37 weeks gestation) infants, 
dosing regimens are often extrapolated from data in adult or older children, increasing the risk of 
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drug side effects and lack of clinical effectiveness (Pineda and Watt, 2015). Dosing regimens 
may be incorrect as they do not account for infants’ developmental changes in renal function, 
metabolic capacity, body composition and surface area, gastrointestinal absorption and immune 
competence. They also showed that ampicillin and gentamycin are the most commonly 
prescribed antibiotics in neonatal ICU which is consistent with the finding in this study.  
Halczli and Adam (2013) further mentioned that medication under dosing could contribute to 
poor treatment outcome, polypharmacy and significant cost to health care system as results of 
potential longer hospital stay. 
 
5.5 The importance of measuring hang time 
This study results showed that in 2017, there were a higher number of doses (46.2%) with hang 
time less than 60 minutes. International standards require that doses should be administered 
within one hour of the prescription being written. It is important to ensure that antibiotics are 
administered timeously to ensure proper management of patients with infections (Messina et al, 
2015). They further pointed out that in relation to the management of patients with severe sepsis 
and septic shock, mortality increases by 7.6 % for every hour of delay in giving antibiotic 
treatment to patients. In addition, they indicated that numerous studies have supported the fact 
that administering antibiotic timeously greatly assist in the improvement of patient outcomes. 
Ferrer et al (2014) in their study of septic patients have shown that patient outcomes were 
negatively impacted irrespective of disease severity or hospital setting when antibiotic treatment 
was late.  
 
In their study, Messina et al (2015) assessed hang time compliance following implementation of 
an antimicrobial stewardship program across 33 hospitals in South Africa. Their study assessed 
32,985 patients who were administered intravenous antibiotic on day 1 for compliance with hang 
time. They observed that 64% patients were administered antibiotics within one hour of written 
prescription and therefore were considered to be hang time compliant. Furthermore, they discuss 
process barriers contributing to hang-time non-compliance. Examples of those barriers include: 
difficulties in getting buy-in from nursing staff to administer a new first dose of antibiotics 
within an hour of the prescription due to of routine standard medicines dosing schedules as well 
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as delayed dispensing process from the pharmacy in case the “stat” dose was not requested by 
the nursing staff. They concluded that ensuring timeous administration of antibiotics therapy 
should be the taken as the first target for “easy win” as low- hanging-fruit component of 
antimicrobial stewardship programme. 
 
5.6 Culture ordering practices 
Culture samples were ordered routinely in most patients and were consistent with the unit’s ICU 
admission process and are supported by Mabila et al (2016). Their study discussed the 
importance of ordering culture samples for accurate diagnosis of infection. They further noted 
that accurate diagnosis will guide the prescriber in decision making related to appropriate choice 
between empiric, prophylactic and specific therapy.  In their study, most indications for 
antibiotic prescriptions were empiric with a few cases where treatment was specific and 
prophylactic. Their observations are consistent with observations in this study, which also 
showed that blood cultures were ordered in 73% of patients in 2016 and 75% of patients in 
2017.This study also concluded that most indications for antibiotic prescriptions were presumed 
empiric in both study periods  
 
5.7 The value of infection markers (CRP) 
As per the ICU unit admission process flow, CRP samples were taken for any admission where 
there is a suspicion of nosocomial infection. The importance of taking CRP measurement as part 
of diagnosis confirmation and decision making in terms of duration of antibiotics therapy is 
supported by various studies. 
 
 CRP is a good selective marker of bacterial sepsis in the newborn (Bomela at el, 2000 and 
Sivanandan et al, 2011). They further pointed out that it has been successfully used historically 
as a marker of infection and is most reliable and effective as a marker between 24 and 48 hours 
after presentation with suspected infection in neonates. In addition, instead of doing one CRP 
measurement, it is recommended to perform several serial CRP assessments in order to have 
sufficient results to guide decision making in terms of de-escalation of antibiotic therapy. Serial 
CRP assessments provides for the assessment of duration of antibiotic therapy resulting in 
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possible reduction in antibiotic therapy duration. Several studies, Ehl et al (1997 ) and Benitz et 
al (1998) assessed the role of CRP measurement as a means to monitor duration of antibiotic 
treatment and confirmed that CRP values that remain negative for more than 24 hours after 
initiation of antibiotic treatment in neonates with suspected sepsis had a negative predictive 
value of 99% and 98.7 % respectively. Those studies showed that clinical application of negative 
CRP allowed the duration of antibiotics treatment to be reduced. Both studies confirmed that the 
use of CRP guided therapy seems to be safe and useful approach in a developing country. 
 
C- reactive protein is useful marker for diagnosed neonatal bacterial infections however it is not 
beneficial for early diagnosis because the levels are elevated in only 35 to 65 % of neonates at 
the start of illness. Numerous studies have appraised the role of serial CRP measurement as a 
guide to the duration of antimicrobial treatment. Philip and Mills (2000) recommended that 
normalization of CRP levels could be taken as criteria to discontinue antibiotic treatment as well 
reducing hospital stay.  CRP level of less than 10 mg/L measured 24 hours after antibiotic 
initiation correctly confirmed 120 of 121 infants as not needing antibiotics therapy continuation 
(Ehl et al, 1997).  
 
5.8 Conclusion  
This chapter reviewed the study results to available literature. There is a porosity of information 
relating the antibiotic utilization in the public sector to which our results could be compared.  
The next chapter will discuss study limitation, recommendations and conclusion. 
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Chapter 6 
 
STUDY LIMITATIONS, RECOMMENDATIONS AND CONCLUSION 
6.1 Introduction  
This chapter discusses limitations of our study, provides recommendations for study site and for 
future research. It also includes the conclusion of the study as well as confirming conflict of 
interest and funding received.  
 
6.2 Study Limitations 
This study was retrospective in design hence it was impossible to confirm information found 
missing with the clinicians or nurses working in the ICU. Missing files and incomplete 
information could not be traced.  
 
Clinicians did not indicate whether the antibiotics were prescribed for empiric, definite or 
prophylactic purpose. This is an important antibiotic stewardship principle (Boyles TH et al, 
2013). 
 
The diagnosis recorded on the ICU related to the diagnosis upon admission and did not always 
correlate to the diagnosis of infection.   
The study period was short and did not take seasonal variation of antibiotic use into account.  
 
6.3 Recommendations for the site and future research  
Electronic dispensing systems can be used to record dispensed medication which can assist in 
determining utilization. The implementation of a computerised system, incorporating the 
microbiology and a decision system assisted in reducing the unnecessary use of broad-spectrum 
antibiotics (Thursky et al, 2006) 
 
Currently the pharmacists at this site are not present in the ward and could be useful intervention 
for future studies.  A close collaboration between, nurses, clinicians and pharmacist has been 
suggested as an approach towards optimizing antibiotic use (Brink et al, 2016). 
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An antibiotic stewardship prescription chart was implemented in the middle of 2017 across the 
hospital and a future study could investigate the impact this has had on utilization.  
Studies such as these provide pertinent information and should be conducted on a regular basis 
especially in the paediatric population where there is a porosity of information. Ongoing 
operational research relating to antibiotic usage is important to inform practices within the unit. 
 
6.4 Conclusion: 
This study reviewed antibiotics prescribed in 95 patients over two periods. A high percentage of 
patients, 47.7% in 2016 and 40% in 2017 were prescribed two antibiotics during their ICU stay. 
Prescription of antibiotics was mostly given empirically for the ICU patients. Ampicillin plus 
gentamycin, imipenem plus vancomycin and meropenem plus vancomycin were the most 
empiric concurrent used antibiotic therapy. This concurrent used therapy was appropriate as it 
covered both the Gram-positive and Gram-negative organisms. Co-amoxiclav was used 
prophylactically in the unit. Cultures and CRP samples were routinely taken upon initiation of 
antibiotics therapy and the results were used to guide further treatment decisions. Duration of 
most antibiotic therapy was five days or less. There was no significant difference between the 
diagnosed conditions between the two study periods. The prescribing of antibiotics was mostly 
aligned to the unit’s policies and guidelines; however there is a need for ongoing surveillance 
and establishment of hospital specific antimicrobial stewardship program which could further 
improve the rational use of antibiotics.     
 
6.5 Conflict of Interest: I declare that there was no conflict of interest in conducting this study. 
 
6.6 Funding: funding for the research was provided by the researcher, there was no external 
funding. 
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Appendix 1: Modified version of the South African Antibiotic Prescription Chart 
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Appendix 2: Hang time 
  
Prescribed Antibiotic 
2016 2017 
Hang time(minutes) Avg 
(Min-Max) 
Hang time(minutes) Avg 
(Min-Max) 
Ampicillin 99 (25-200)  205(30-510) 
Amikacin  166 (30-560)  65(10-120) 
Cefotaxime  155 (0-325)  167(60-465) 
Ceftriaxone  70 (0-140)  26(24-30) 
Cefazolin  157 (15-300)  190(0-315) 
Co-amoxiclav  124 (60-263)  81(0-333) 
Co-trimoxazole  146 (80-240)  N/A 
Colistin  N/A  236(236-236) 
Cloxicillin  126 (15-236)  120(120-120) 
Chloramphenicol  N/A  N/A 
Doxycycline  N/A  0 
Ertapenem  270 (270-270)  N/A 
Erythromycin  178 (25-420)  N/A 
Gentamicin  85 (25-200)  160(35-285) 
Imipenem/cilastin  153 (0-600)  N/A 
Meropenem  235 (140-330)  113(15-420) 
Piperacillin/tazobactam  138 (50-330)  46(0-120) 
Rifampicin  N/A  0 
Vancomycin  141 (30-375)  70(15-150) 
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Appendix 3: Diagnosed Conditions 
Diagnosed conditions 2016 Diagnosed conditions 2017 
Meconium Aspiration (Medical) Head injury, extradural hemorrhage(Surgery) 
Post Adnectomy & Tonsillectomy (Surgery) ILEO- colic intussusception(Surgery)) 
Respiratory distress syndrome (Medical) AKI (Medical) 
Pneumonia (Infection) Intussusception, post exploratory laparotomy and 
hemicolectomy (Surgery) 
SIMD (Medical) Spontaneous bacterial peritonitis (Infection) 
Respiratory distress syndrome (Medical) Bowel  obstruction of distal ileum day1 post laparotomy 
(Surgery) 
Bronchospasm (Medical) Laparotomy, jejunal atresia, sepsis (Infection) 
Perforated necrotizing enterocolitis (infection) Pneumoperitoneum Medical) 
Congenital heart block (Medical) TBM stage 3, milirary TB, septic shock (Infection) 
Correction of sclerosis and vertebrae column resection 
(Surgery) 
Tonsillectomy (Surgery) 
Insertion of VP shunt (surgery) Nephrectomy/Laparotomy (Surgery) 
Cyanotic heart disease (Medical) Hepatoblastoma (Medical) 
Post repair cleft palate (Surgery) Cyanotic heart disease, critical pulmonary sepsis 
(Infection) 
Post EVD and myelomeningocele repair (Surgery) Post-surgery posterior fossa mass resection (Surgery) 
Incision and drainage RT-Tibig (Surgery) Previous tracheoesophageal repair, duodenal stenosis 
cardiac arrest, tracheostomy (Surgery) 
Exploratory Laparotomy for bowel obstruction (Surgery) Previous tof repair, rigid oesophagoscopy for coin removal 
(Surgery) 
LBW Gastroschisis (Surgery) Traumatic brain injury, subarachnoid hemorrhage, left 
parietal subdural skull fracture (Surgery) 
MSL Grade III (medical) T18- Known to RMHC, community acquired pneumonia 
(Infection) 
Pulmonary Hemorrhage (Medical) Ex prem, prev nec- bowel obstruction adhesions (Surgery) 
VP Shunt (Surgery) Pyoderma gangrenous stridor, necrotic ulcers (Medical) 
RDS (Medical) Tonsillectomy (Surgery) 
PCP (infection) Nephrectomy/Laparotomy (Surgery) 
Hereditary multiple Osteochondromas (Medical) Hepatoblastoma-post (Medical) 
Coarctution of aorta (Surgery) Cyanotic Heart disease- critical pulmonary stenosis 
(Medical) 
Respiratory distress Preterm (Medical) Post-surgery posterior fossa mass resection (Surgery) 
Crainostomy PVA MVA (Surgery) Pneumothorax (Infection) 
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Diagnosed conditions 2016 Diagnosed conditions 2017 
Incision and Drainage RT-Tibig (Surgery) Previous tracheoesophageal repairs/Duodenal stenosis 
(Surgery) 
Hemicolectomy ileostomy (Surgery) Twin/hmd-svt-ippv- method for ventilation 
GNB sepsis (Infection) RVD exposed/gastroschisis (Surgery) 
Bronchopneumonia (Infection) Meconium Aspiration syndrome(medical) 
Severe respiratory distress, metabolic acidosis, 
rash(medical) 
Hmd-svt-ncpap/preterm method for ventilation 
Jugular artery repair(surgery) Malrotation volvulus(surgery) 
Perforated NEC(surgery) Spinalbifida, Meningitis(Infection) 
Respiratory distress syndrome(Medical) Ulcer left foot (Medical) 
Gastrossclosis(surgery) Hydrocephaly(medical) 
Exploratory Laparotomy(surgery) Pneumonia(infection) 
Nosocomial infection/Pneumonia(infection) Anemia/seizures(medical) 
Sepsis(infection) Rectal Perforation(Surgery) 
Bilateral inguinale hernia repair(surgery) Malrotation(Surgery) 
Debridement of right hand(surgery)  
Post exploratory Laparotomy(surgery)  
Severe respiratory acidosis, NEC, Sepsis(infection)  
Post cricoid split(surgery)  
Meningococcal hydrocephalous(infection)  
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Appendix 4: Protocol approval 
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Appendix 5: Ethical clearance letter 
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Appendix 6: Hospital approval letter 
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Appendix 7: 2016 Doses given versus calculated SAMF doses 
Patient 
Numbers 
  
  
Antibiotic 1 
  
  
Antibiotic 2 
  
  
Antibiotic 3 
  
  
Antibiotic 4 
  
  
Antibiotic 5 
  
Antibiotic 
Dose 
Given 
SAMF(2016) 
Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose antibiotic 
Dose 
Given 
SAMF 
(2016)Dose Antibiotic Dose Given 
 
 
2016/1 Tazocin 2.6 2.71 Amikacin 400 406 Cloxicillin 1 1.4             
2016/2 Augmentin 250 380                         
2016/3 Ampicillin 150 153 Gentamycin 15 18                   
2016/4 Ampicillin 55 55 Gentamycin 5 6.5                   
2016/5 Ampicillin 200 235 Gentamycin 20 38                   
2016/6 Ertapenem 280 285 Vancomycin 200 285 Amikacin 280 342             
2016/7 Ampicillin 230 220 Gentamycin 22 26 Bactrim 40 44             
2016/8 Kefzol 120 184 Cefotaxime 190 184 Imipenem 75 92 Vancomycin 55 55       
2016/9 Amikacin 375 375 Tazocin 1 2.5                   
2016/10 Imipenem 37 37 Vancomycin 22 22                   
2016/11 Ampicillin 280 280 Gentamycin 30 33 Erythromycin 55 56             
2016/12 Vancomycin 30 42 Imipenem 70 71                   
2016/13 Vancomycin 18 24 Imipenem 40 41 Amikacin 24 24             
2016/14 Tazocin 250 340 Amikacin 50 51 Erythromycin 35 34             
2016/15 Cloxicillin 210 215 Cefotaxime 250 215                   
2016/16 Vancomycin 10 16 Imipenem 25 27                   
2016/17 Imipenem 38 48 Vancomycin 20 28                   
2016/18 Ampicillin 220 220 Gentamycin 20 26 Bactrim 38 44 Tazocin 400 440 Amikacin 60  
2016/19 Imipenem 40 40 Vancomycin 16 24                   
2016/20 Augmentin 100 170 Vancomycin 34 51                   
2016/21 Augmentin 300 500                         
2016/22 Imipenem 29 30 Vancomycin 16 18                   
2016/23 Kefzol 700 1250 Amikacin 375 375 Tazocin 1 2.5             
2016/24 Augmentin 100 170 Cefotaxime 85 85                   
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Numbers 
  
  
Antibiotic 1 
  
  
Antibiotic 2 
  
  
Antibiotic 3 
  
  
Antibiotic 4 
  
  
Antibiotic 5 
  
Antibiotic 
Dose 
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SAMF(2016) 
Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose antibiotic 
Dose 
Given 
SAMF 
(2016)Dose Antibiotic Dose Given 
 
 
2016/25 Imipenem 60 57 Vancomycin 25 34 Meropenem 60 46             
2016/26 Cefotaxime 270 200 Bactrim 60 54 Ampicillin 200 200             
2016/27 Imipenem 30 26 Meropenem 40 42                   
2016/28 Imipenem 45 46 Vancomycin 17 28                   
2016/29 Ampicillin 70 72 Gentamycin 7 9                   
2016/30 Ampicillin 180 180 Gentamycin 18 21                   
2016/31 Ampicillin 90 87 Gentamycin 9 10 Imipenem 50 43             
2016/32 Imipenem 36 29 Vancomycin 12 18                   
2016/33 Imipenem 30 29 Vancomycin 12 17                   
2016/34 Kefzol 100 120                         
2016/35 Ampicillin 72 72 Gentamycin 7 7 Imipenem 35 36             
2016/36 Augmentin 60 110 Imipenem 44 55 Vancomycin 22 33             
2016/37 Augmentin 360 600                         
2016/38 Gentamycin 5 6 Imipenem 20 26 Vancomycin 15 15             
2016/39 Ceftriaxone 140 141 erythromycin 28 28 Tazocin 280 283 Amikacin 42 42       
2016/40 Rocephin N/A                           
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Appendix 8: 2017 Doses given versus calculated SAMF doses 
Patient 
Numbers 
  
  
Antibiotic 1 
  
  
Antibiotic 2 
  
  
Antibiotic 3 
  
  
Antibiotic 4 
  
  
Antib   
  
Antibiotic 
Dose 
Given 
SAMF(2016) 
Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose Antibiotic 
Dose 
Given 
SAMF 
(2016)Dose antibiotic 
Dose 
Given 
SAMF(2016) 
Dose Antibiotic Dose  
 
 
2017/1 Vancomycin 15 16 Meropenem 45 45                   
2017/2 n/a     n/a     n/a                 
2017/3 Meropenem 70 71 Vancomycin 26 27 Cefotaxine 120 89 Colistin 80000 75000       
2017/4 Meropenem 240 240 Vancomycin 186 80                   
2017/5 Meropenem 65 63 Vancomycin 24 23                   
2017/6 Ampicillin 160 161 Gentamycin 16 19 Meropenem 65 64 Vancomycin 48 48       
2017/7 Ampicillin 56 56 Gentamycin 5.6 6.7 Meropenem 42 45 Vancomycin 15 17       
2017/8 Ampicillin 190 185 Gentamycin 19 22                   
2017/9 Augmentin 43 43 Meropenem 120 114 Vancomycin 40 43 Cefotaxime 190 143       
2017/10 Augmentin 120 132                         
2017/11 Ampicillin 55 55 Gentamycin 5.5 6.6                   
2017/12 Cefotaxime 400 595 Cloxacillin 600 595 Augmentin 325 595             
2017/13 Ampicillin 100 100 Gentamycin 10 12                   
2017/14 Meropenem 48 48 Vancomycin 18 18 Colistin 48000 75000             
2017/15 Cefazolin 360 165/550                         
2017/16 Meropenem 45 45 Vancomycin 17 17 Colistin 45200 45200             
2017/17 Augmentin 360 580 Meropenem 465 464 Vancomycin 175 174             
2017/18 Meropenem 56 56 Vancomycin 14 21                   
2017/19 Meropenem 125 132 Vancomycin 50 50                   
2017/20 Meropenem 36 37 Vancomycin 14 14                   
2017/21 Cefazolin 200 210                         
2017/22 Cefotaxime 140 105                         
2017/23 Ampicillin 125 128 Gentamycin 12.5 15                   
2017/24 Ceftriaxone 375 375                         
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2017/25 Augmentin 250 450                         
2017/26 Meropenem 43 43 Vancomycin 16 16                   
2017/27 Cefazolin 400 600 Meropenem 480 480 Vancomycin 180 180             
2017/28 Ampicillin 100 98 Gentamycin 9.5 12                   
2017/29 Cefazolin 1g 1.9                         
2017/30 Cefotaxime 275 205 Meropenem 160 164 Vancomycin 60 61             
2017/31 Meropenem 80 104                         
2017/32 Augmentin 145 240 Meropenem 205 192 Vancomycin 77 72             
2017/33 Augmentin 120 185                         
2017/34 Ceftriaxone 1800 1350 Doxycycline 100 90 Rifampicin 360 360             
2017/35 Ampicillin 47 48 Gentamycin 4.7 5.7                   
2017/36 Augmentin 180 280 Vancomycin 115 84 Amikacin 85 84             
2017/37 Meropenem 55 54 Vancomycin 21 21 Cefotaxime 88 69 Chloramphenicol Not clear 55 Colistin 5280   
2017/38 Ampicillin 130 133 Gentamycin 13 16                   
2017/39 Augmentin 65 110                         
2017/40 Augmentin 325 650                         
2017/41 Tazocin 2 2.6 Amikacin 400 390                   
2017/42 Ampicillin 150 152 Gentamycin 15 18                   
2017/43 Meropenem 138 138 Vancomycin 52 52                   
2017/44 Augmentin 180 305                         
2017/45 Augmentin 225 450 Tazocin 900 900 Amikacin 135 135             
2017/46 Cefotaxime 200 175 Vancomycin 53 53                   
2017/47 Meropenem 32 32 Vancomycin 12 12                   
2017/48 Ampicillin 150 153 Gentamycin 15 19                   
2017/49 Tazocin 550 740 Meropenem 140 148                   
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2017/50 Augmentin 120 225                         
2017/51 Meropenem 40 45 Vancomycin 17 17                   
2017/52 Ceftriaxone 2 3.2                         
2017/53 Meropenem 450 440 Vancomycin 170 165 Amikacin 165 165             
2017/54 Ampicillin 100 109 Tazocin 100 109 Meropenem 40 44             
2017/55 Tazocin 280 289 Amikacin 20 43 Vancomycin 28 44             
2017/56 Augmentin 150 295 Meropenem 120 118 Vancomycin 90 89             
2017/57 Meropenem 124 124 Vancomycin 47 47                   
 
 
 
 
 
 
